Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 9
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Market Definition - Infoholic Research 14
3.2 Segmented Addressable Market (SAM) 14
3.3 Industry Trends 15
3.4 Related Markets 16
3.4.1 Active pharmaceutical ingredients (APIs) 16
3.4.2 Over-the-counter drugs (OTC) 16
3.4.3 Human Insulin 17
4 Market Outlook 19
4.1 Market Segmentation 19
4.2 Porter 5 (Five) Forces 19
5 Market Characteristics 22
5.1 Market Dynamics 22
5.1.1 Drivers 23
5.1.1.1 High incidence of chronic kidney disease (CKD) 23
5.1.1.2 Rise in incidence of cardiovascular disorders and diabetes 23
5.1.1.3 Increase in global geriatric population 23
5.1.2 Restraints 24
5.1.2.1 Competition from biosimilars 24
5.1.2.2 Complex drug development process 25
5.1.3 Opportunities 25
5.1.3.1 Promising Drug Pipeline Chronic Kidney Disease 25
5.1.3.2 Market expansion opportunities in emerging nations 27
5.1.3.3 Novel therapeutic approaches such as cell therapy 27
5.1.4 DRO - Impact Analysis 28
5.2 Key Stakeholders 29
6 Drug Class: Market Size and Analysis 30
6.1 Overview 30
6.2 Anti-hypertensives 31
6.1 Anti - hyperlipidemic 32
6.2 Erythropoiesis-stimulating agents (ESAs) 33
6.3 Diuretics Drugs 35
6.4 Others 36
7 End Users: Market Size and Analysis 38
7.1 Overview 38
7.2 Hospitals 38
7.3 Specialty Clinic 39
8 Regions: Market Size and Analysis 40
8.1 Overview 40
8.2 North America 42
8.2.1 Overview 42
8.3 Europe 43
8.3.1 Overview 43
8.4 Asia Pacific 45
8.4.1 Overview 45
8.5 Rest of the World 46
8.5.1 Overview 46
9 Competitive Landscape 49
10 Vendors Profile 51
10.1 AbbVie Inc. 51
10.1.1 Overview 51
10.1.2 Geographic Presence 54
10.1.3 Business Focus 54
10.1.4 SWOT Analysis 55
10.1.5 Business Strategies 55
10.2 Amgen Inc. 56
10.2.1 Overview 56
10.2.2 Geographic Presence 59
10.2.3 Business Focus 59
10.2.4 SWOT Analysis 59
10.2.5 Business Strategies 60
10.3 GlaxoSmithKline plc 60
10.3.1 Overview 60
10.3.2 Geographic Presence 63
10.3.3 Business Focus 64
10.3.4 SWOT Analysis 64
10.3.5 Business Strategies 65
10.4 F. Hoffmann-La Roche Ltd. 66
10.4.1 Overview 66
10.4.2 Business Units 67
10.4.3 Geographic Revenue 68
10.4.4 Business Focus 69
10.4.5 SWOT Analysis 69
10.4.6 Business Strategies 70
10.5 Astra Zeneca PLC 71
10.5.1 Overview 71
10.5.2 Geographic Presence 75
10.5.3 Business Focus 75
10.5.4 SWOT Analysis 76
10.5.5 Business Strategies 76
11 Companies to Watch for 77
11.1 Pfizer Inc. 77
11.1.1 Overview 77
11.2 Sanofi 78
11.2.1 Overview 78
11.3 Teva Pharmaceutical Industries Ltd. 79
11.3.1 Overview 79
11.4 Johnson & Johnson 80
11.4.1 Overview 80
11.5 Keryx Biopharmaceuticals Inc 81
11.5.1 Overview 81
11.6 FibroGen Inc. 82
11.6.1 Overview 82
Annexure 84
? Acronyms 84

?